This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Ceritinib and crizotinib can slow the breakdown of some medications such as cyclosporine, dihydroergotamine, ergotamine, pimozide, quinidine, sirolimus, and tacrolimus.
What might happen:
If the blood level of your medicine increases you may have an increase in side effects.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Ask your pharmacist what side effects to look for and report for the medicine you are taking.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Zykadia (ceritinib) US prescribing information. Novartis Pharmaceuticals Corporation July, 2017.
2.Xalkori (crizotinib) US prescribing information. Pfizer Inc. April, 2016. 3.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
3.FDA. CDER Application number: 205755 Zykadia (ceritinib) CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S). available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000Clin PharmR.pdf March 25, 2014.